Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference
LUND, SE / ACCESS Newswire / March 6, 2025 /Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025.
Fireside chat
Damian Marron, interim CEO, will participate in a fireside chat moderated by Joe Pantginis, Managing Director, Equity Research at H.C. Wainwright & Co., LLC.
March 27 at 08.00am EST (13.00pm CET).
Live webcasting link: https://journey.ct.events. An archived link to the webcast will be available through the Newsroom section on Cantargia 's homepage at https://cantargia.com. The archived webcast will be available for replay for at least 30 days.
For further information, please contact
Damian Marron, Interim CEO
Telephone: +46 (0)46-275 62 60
E-mail: damian.marron@cantargia.com
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia 's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia 's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
Attachments
Cantargia to Participate at H.C. Wainwright 's Annual Autoimmune & Inflammatory Virtual Conference
SOURCE: Cantargia
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
